v3.26.3
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Revenue $ 68,298 $ 70,445 $ 264,510 $ 976,340
Cost of sales 23,488 21,496 68,429 50,936
Research and development expenses:        
Selling, general, and administrative expense 23,645 31,655 79,087 123,357
Other segment income (expense) (95) (121,399) 7,363 (112,828)
Net income (loss) (31,376) (202,379) (94,254) 422,775
Reportable Segment        
Segment Reporting [Line Items]        
Revenue 68,298 70,445 264,510 976,340
Cost of sales 23,488 21,496 68,429 50,936
Research and development expenses:        
Employee and benefit expenses 30,165 35,270 99,040 111,330
Facility and other research and development expenses 10,225 22,269 44,238 64,936
Selling, general, and administrative expense 23,645 31,655 79,087 123,357
Net income (loss) (31,376) (202,379) (94,254) 422,775
Reportable Segment | Direct COVID-19 Vaccine        
Research and development expenses:        
Supplier finance programs 8,270 26,534 62,598 55,358
Reportable Segment | Direct CIC and influenza vaccines        
Research and development expenses:        
Supplier finance programs (1,169) 12,987 2,387 32,607
Reportable Segment | Direct other vaccine development programs        
Research and development expenses:        
Supplier finance programs $ 4,955 $ 1,214 $ 10,348 $ 2,213